The advantage of such treatment, in theory, relies on the fact that, unlike cytotoxic drugs, which give rise to many off-target side effects to normal tissues, the release of drug to cancer cells acts directly on specific molecular targets (overexpressed protein such as her2neu or EGFR and ALK) that are associated with cancer. This evidence concerns the gene EGFR and cancer.